Author

G. Favre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

A. Carrier· 1 shared A. Casanova· 1 shared A. Delaunay· 1 shared A. Delmas· 1 shared A. Maraver· 1 shared A. Pradines· 1 shared C. Delahaye· 1 shared C. Desjobert· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Carrier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness

A. Carrier, C. Desjobert, L. Ponger, L. Lamant, M. Bustos, J. Torres-Ferreira, R. Henrique, C. Jeronimo, L. Lanfrancone, A. Delmas, G. Favre, A. Delaunay, F. Busato, D. S. B. Hoon, J. Tost, , P. B. Arimondo

The paper identifies a DNA methylation signature associated with melanoma aggressiveness using a multi-step genomic pipeline across different host environments.

bioRxiv · Apr 11, 2022Cancer Biology

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

S. Figarol, C. Delahaye, R. Gence, R. Asslan, S. Pagano, C. Tardy, J. Colinge, J.-P. Villemin, A. Maraver, I. Ferrer, L. Paz-Ares, I. Lajoie-Mazenc, E. Clermont, A. Casanova, A. Pradines, , G. Favre

This study identifies early escapers as a rare cell population resistant to EGFR-TKi and shows that tipifarnib overcomes this resistance by targeting Rho/ROCK pathway and preventing relapse.

bioRxiv · Apr 1, 2022 · PreprintCancer Biology